Clinical Trial Update: Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and tolerability of intravenously administered PYC-003 for autosomal dominant polycystic kidney disease. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• PYC-003

Snippet

Sponsor: PYC Therapeutics | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | Status: RECRUITING